Senior Manager, Finance Business Partner

Zealand Pharma A/S; Denmark; On-site; DKK 800,000 - 1,100,000; Full time

Job summary

Zealand Pharma A/S in Copenhagen, Denmark, is seeking a Finance Business Partner to act as trusted financial advisor to Global Project Leads across the Development portfolio. Focus on forward-looking analysis, scenario planning, and business cases, not month-end accounting.

You will partner with project teams, manage budgeting and outlooks, drive business cases for governance, and lead finance projects spanning the organization. Fluency in English and a finance degree are essential.

Qualifications

• Experience in a finance partner role in pharma or biotech.
• Strong analytical and financial modeling skills.
• Fluent in English, written and spoken.

Responsibilities

• Operate as a business partner to project teams, including project leaders and team members, across a portfolio of development projects.
• Drive development of business cases for governance body endorsements, toll gate passes, and portfolio value updates.
• Take on a Finance lead role in selected strategic finance projects.
• Manage the planning process (budget, outlook) for relevant development projects.
• Manage reporting, follow-up analyses, and action planning to close performance gaps, including scenario building and business steering.
• Act as a healthy challenger to project teams and departments, asking why, how and so what, capable of smooth internal negotiations and being a trusted sounding board.

Skills

Strategic mindset

Financial analysis

Financial modeling

Fluent in English

Education

Degree in Finance or Economics

Job description

Does it excite you to shape strategic decisions through finance and close business partnering? And do you have experience with financial planning, cross-functional collaboration, and turning insights into measurable results? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position as Finance Business Partner will be the trusted financial advisor to our Global Project Leads across the Development portfolio. You will focus on forward-looking analysis, scenario planning and business cases, rather than month-end controlling or technical accounting, proactively challenging assumptions and connecting financial insights into operational decisions. You will also be responsible for wider Finance Projects that span across our Zealand organization. This role offers extensive cross-functional exposure and visibility across the organization.

Responsibilities

• Operate as a business partner to project teams, including project leaders and individual project team members, across a portfolio of development projects
• Drive development of business cases for relevant development projects, for example for governance body endorsements, toll gate passes, and portfolio value updates
• Take on a Finance lead role in selected strategic finance projects
• Manage the planning process (budget, outlook) for relevant development projects
• Manage reporting, follow-up analyses, and action planning to close performance gaps, including scenario building and business steering
• Act as a healthy challenger to project teams and departments, asking "why", "how" and "so what?", capable of smooth internal negotiations and being a trusted sounding board

Profile & Qualifications

• You have a strategic mindset and are comfortable challenging senior stakeholders constructively, and confident acting as a trusted sounding board across the organization.
• Experience from a likewise position or financial analysis position Pharma or biotech industry experience is preferred.
• Strong analytical and financial modeling skills.
• Fluent in English, written and spoken.
• Degree in Finance, Economics, or a related field.

Team & Reporting

You will join the FP&A and Finance Business Partnering team, reporting to the Head of FP&A and Finance Business Partnering, as part of Finance & Accounting - where we see ourselves as business partners to the whole organization.

Culture & Values

Lets bond and be bold. We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation.

For further information, please contact Head of FP&A and Finance Business Partnering, Emilie Kirk Madsen, [e-mail].

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

Learn more at www.zealandpharma.com.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts.

Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.